Scleroderma: DR antigens, autoantibodies and clinical manifestations.
The relationship between anticentromere antibodies (ACA), antitopoisomerase I or Scleroderma 70 (Scl-70) antibodies, HLA-DR antigens, and clinical manifestations of scleroderma were examined in 51 patients defined by ARA criteria. No association between a given HLA-DR antigen and either ACA or anti-Scl-70 was found. Statistically significant associations were noted for patients with ACA who had a lower frequency of arthritis and longer disease duration; anti-Scl-70 patients were more likely to be males with a higher frequency of pulmonary, cardiac and sicca symptoms.
Alarcón
G S
GS
Department of Medicine (Division of Clinical Immunology and Rheumatology), School of Medicine, University of Alabama at Birmingham 35294.
McCarty
G A
GA
Lanyon
P
P
Phillips
R M
RM
Acton
R T
RT
Barger
B O
BO
D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D001323:Autoantibodies / Q000032:analysis*; D002503:Centromere / Q000276:immunology; D004264:DNA Topoisomerases, Type I; D005260:Female; D005455:Fluorescent Antibody Technique; D006681:HLA-D Antigens / Q000032:analysis*; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000276:immunology; D012595:Scleroderma, Systemic / Q000276:immunology*
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D006681:HLA-D Antigens; D006684:HLA-DR Antigens; D009687:Nuclear Proteins; C048100:Scl 70 antigen, human; D004264:DNA Topoisomerases, Type I